Navigation Links
Old and new therapies combine to tackle atherosclerosis
Date:9/15/2008

Fumagillin nanoparticles could be used to further inhibit the development of new vessel treatment in high-risk patients, Lanza says.

"Our past research showed that fumagillin nanoparticles reduced blood vessel formation at the site of arterial plaques in experimental rabbits after one week," says Lanza. "In this study, we tested how long that effect lasts and if it could be extended by statins."

The rabbits used in the study ate a high-fat diet that caused arterial plaques. The researchers detected new blood vessel buildup at the site of plaques by coating nanoparticles that were targeted to neovessels with an MRI contrast agent.

When the rabbits received a single dose of blood-vessel-targeted nanoparticles that also carried fumagillin, the researchers saw that the amount of MRI signal at the sites of plaques decreased about five-fold by the end of one week. But a high MRI signal returned by the fourth week, indicating that plaques were active again.

Because repeated injections of fumagillin nanoparticles is impractical for treating human patients, the researchers looked for a way to extend the initial effectiveness.

Atherosclerotic rabbits that got daily doses of the statin atorvastatin (brand name Lipotor) had no change in plaque angiogenesis measured by MRI. When the statin and the fumagillin nanoparticles were started at the same time, the atorvastatin had no additional benefits over the targeted therapy.

However, when the statin had been given for at least one month prior to the fumagillin treatment, the five-fold reduction in MRI signal due to diminished neovessels was maintained for four weeks.

Lanza says that the results suggest that one or possibly two injections of nanoparticles in patients who are already on statins could lead to a long-term reduction in plaque activity and prolonged plaque stability. The results also illustrate the potential clinical use of MRI molecular imaging with the neovessel-targeted nanoparticle
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
3. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
4. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
5. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
6. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
7. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
8. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
9. Organogenesis, Inc. to Develop Regenerative Medicine Therapies for U.S. Military Battlefield Injuries
10. Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
11. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
(Date:2/26/2015)... PHILADELPHIA , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... its management team will participate in the Cowen and ... at 9:40 a.m., Eastern, at the Boston Marriott Copley ... a Spark Therapeutics presentation from the Cowen conference, please ... Events" section of the Spark Therapeutics website at ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... ionized gas to carve tiny components on silicon wafers) ... the observation that the number of transistors that can ... two years. Without the compensating capabilities of plasma etching, ... sizes at about 1 micron (the diameter of a ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, ... its financial results for the third quarter of 2011. ... Increased 24.0% Year Over Year to $104.0 Million ...
... Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm (the "Company") ... (HIV) infections, today announced its financial results for the ... reported a net loss of $375,852 ($0.02 per share) ... to $644,666 ($0.04 per share) for the same period ...
Cached Biology Technology:Plasma etching pushes the limits of a shrinking world 2WuXi PharmaTech Announces Third-Quarter 2011 Results 2WuXi PharmaTech Announces Third-Quarter 2011 Results 3WuXi PharmaTech Announces Third-Quarter 2011 Results 4WuXi PharmaTech Announces Third-Quarter 2011 Results 5WuXi PharmaTech Announces Third-Quarter 2011 Results 6WuXi PharmaTech Announces Third-Quarter 2011 Results 7WuXi PharmaTech Announces Third-Quarter 2011 Results 8WuXi PharmaTech Announces Third-Quarter 2011 Results 9WuXi PharmaTech Announces Third-Quarter 2011 Results 10WuXi PharmaTech Announces Third-Quarter 2011 Results 11WuXi PharmaTech Announces Third-Quarter 2011 Results 12WuXi PharmaTech Announces Third-Quarter 2011 Results 13WuXi PharmaTech Announces Third-Quarter 2011 Results 14WuXi PharmaTech Announces Third-Quarter 2011 Results 15WuXi PharmaTech Announces Third-Quarter 2011 Results 16WuXi PharmaTech Announces Third-Quarter 2011 Results 17WuXi PharmaTech Announces Third-Quarter 2011 Results 18GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Science at the New York Academy of Sciences will ... "Frontiers in Agricultural Sustainability: Studying the Protein Supply Chain ... protein innovations in food science and programming that are ... protein to consumers worldwide. A full agenda can ...
... - 14 November 2013 The world should aim to ... are capable of eliminating malaria, licensed by 2030, according to ... new target comes in addition to the original 2006 Roadmap,s ... the most deadly form of the disease, for children under ...
... its recent research on the face biometrics market, ... the 2013 European Frost & Sullivan Award for ... biometrics earned the company strong domain expertise, which ... recognition technology, FaceVACS-VideoScan. FaceVACS-VideoScan analyses live ...
Cached Biology News:New malaria vaccines roadmap targets next generation products by 2030 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: